Johnson & Johnson Clinical Trials: 2,499 Led Studies

Archive historyOct 2022 to Jul 2026

123 recorded changes across Johnson & Johnson trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 36 of these trials. One is shown below.

Completion date movePrimary completion moved 456 days laterNCT04634552 · recorded 1 Jun 2026

Track to read them

+119 more recorded changes · Track a drug to see every change the night it lands

Track guselkumab

Most active programmes

The drugs appearing most often across Johnson & Johnson's recently active trials. Comparator arms are excluded.

Talquetamab9 trials
Guselkumab9 trials
Teclistamab7 trials
Apalutamide5 trials
Amivantamab5 trials
Nipocalimab4 trials

Upcoming readouts

Next primary completion dates among Johnson & Johnson's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Dec 2026Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Ma…Phase 3
Dec 2026CAN3001: A Long-term Extension Study of PCI-32765 (Ibrutinib)Phase 3
Jan 2027PLATYPUS: A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Pare…Phase 3
Feb 2027Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Back…Phase 2
May 2027Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Poly…Phase 2
Jun 2027TRIlogy-3: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaPhase 2

Top therapeutic areas

Conditions studied most often across Johnson & Johnson's recently active trials.

Multiple Myeloma12 trials
Colitis, Ulcerative8 trials
Crohn's Disease6 trials
Arthritis, Psoriatic5 trials
Prostatic Neoplasms5 trials
Neoplasms4 trials

Johnson & Johnson trials

The 50 most significant of Johnson & Johnson's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric StudiesNCT02494986Rilpivirine	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	48 est.	18 Aug 2026
LIBERTASA Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPCNCT05884398Apalutamide	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	420 est.	12 Oct 2026
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed TherapiesNCT05453903Bleximenib	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	196 est.	30 Oct 2026
PROTEUSA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyNCT03767244Apalutamide	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	2,517 est.	1 Dec 2026
OPALAn Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative ColitisNCT02808780	—	Not yet scored	OngoingActive, not recruiting	535 est.	10 Dec 2026
A Study of JNJ-89862175 for Treatment of Advanced Solid TumorsNCT07223125JNJ-89862175	Phase 1	Locked · track to reveal	OngoingRecruiting	360 est.	15 Dec 2026
ReτainA Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseNCT06544616JNJ-64042056	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	55 est.	22 Dec 2026
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsNCT06559306Seltorexant	Phase 3	Locked · track to reveal	OngoingRecruiting	752 est.	30 Dec 2026
SunRISe-2A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderNCT04658862Cetrelimab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	518 est.	30 Dec 2026
CAN3001A Long-term Extension Study of PCI-32765 (Ibrutinib)NCT01804686Ibrutinib	Phase 3	Locked · track to reveal	OngoingRecruiting	700 est.	31 Dec 2026
ARX517ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate CancerNCT04662580ARX517	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	183 est.	31 Dec 2026
PLATYPUSA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionNCT05179876Macitentan	Phase 3	Locked · track to reveal	OngoingRecruiting	280 est.	31 Jan 2027
PolyDamasA Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerNCT05908734Cetrelimab	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	71 est.	31 Jan 2027
QUASAR JrA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisNCT06260163Guselkumab Subcutaneous	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	112 est.	10 Feb 2027
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TBNCT02354014Bedaquiline (TMC207)	Phase 2	Locked · track to reveal	OngoingRecruiting	60 est.	11 Feb 2027
CARTITUDE-2A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple MyelomaNCT04133636JNJ-68284528	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	208 est.	26 Feb 2027
A Study of JNJ-87890387 for Advanced Solid TumorsNCT06178614JNJ-87890387	Phase 1	Locked · track to reveal	OngoingRecruiting	200 est.	16 Mar 2027
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate CancerNCT04898634JNJ-78278343	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	216 est.	31 Mar 2027
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple MyelomaNCT04108195Daratumumab	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	290 est.	7 Apr 2027
OrigAMI-1A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal CancerNCT05379595Amivantamab IV	Phase 1	Locked · track to reveal	OngoingRecruiting	225 est.	27 Apr 2027
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NCT05327114Nipocalimab	Phase 2	Locked · track to reveal	OngoingRecruiting	201 est.	14 May 2027
REASONTransmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease PatientsNCT06408935Guselkumab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	120 est.	8 Jun 2027
TRIlogy-3A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaNCT07266441JNJ-79635322	Phase 2	Locked · track to reveal	OngoingRecruiting	157 est.	14 Jun 2027
MonumenTAL-1A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaNCT04634552Talquetamab	Phase 2	Locked · track to reveal	OngoingRecruiting	510 est.	30 Jun 2027
GURUA Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World SettingNCT07220824	—	Locked · track to reveal	OngoingRecruiting	200 est.	31 Jul 2027
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic NeoplasmsNCT06651229JNJ-90189892	Phase 1	Locked · track to reveal	OngoingRecruiting	155 est.	5 Aug 2027
MonumenTAL-8A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple MyelomaNCT06550895Cilta-cel	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	11 est.	26 Aug 2027
EPICComparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia GravisNCT07217587Nipocalimab	Phase 3	Locked · track to reveal	OngoingRecruiting	115 est.	28 Sept 2027
MACARONI-23A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseNCT05923073Guselkumab	Phase 3	Locked · track to reveal	OngoingRecruiting	120 est.	27 Oct 2027
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple MyelomaNCT06604715JNJ-87562761	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	17 est.	3 Nov 2027
TRI ProA Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple MyelomaNCT07589634Ramantamig	Phase 2	Locked · track to reveal	OngoingRecruiting	230 est.	31 Dec 2027
DAFFODILNipocalimab in Moderate to Severe Sjogren's DiseaseNCT06741969Nipocalimab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	655 est.	1 Jan 2028
ICONIC-UCA Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative ColitisNCT07196748Icotrokinra	Phase 3	Locked · track to reveal	OngoingRecruiting	882 est.	14 Jan 2028
A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringNCT06788509JNJ-75348780	Phase 1	Locked · track to reveal	OngoingEnrolling by invitation	120 est.	19 Jan 2028
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric CancersNCT06663319JNJ-89402638	Phase 1	Locked · track to reveal	OngoingRecruiting	260 est.	25 Feb 2028
AmiNAA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCNCT07586202Amivantamab	Phase 2	Locked · track to reveal	OngoingRecruiting	68 est.	2 Mar 2028
MoMMentA Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple MyelomaNCT05160584	—	Not yet scored	OngoingRecruiting	300 est.	30 Apr 2028
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid MalignanciesNCT07308132JNJ-95566692	Phase 1	Locked · track to reveal	OngoingRecruiting	130 est.	31 Aug 2028
PROGRESS-ROA Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in RomaniaNCT07582783	—	Locked · track to reveal	OngoingRecruiting	200 est.	15 Sept 2028
GARDENIA-SLEA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus ErythematosusNCT07438496Nipocalimab	Phase 3	Locked · track to reveal	OngoingRecruiting	600 est.	6 Dec 2028
TRIlogy-4A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaNCT07258511JNJ-79635322	Phase 3	Locked · track to reveal	OngoingRecruiting	400 est.	12 Dec 2028
REALITY-ROA Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic LeukemiaNCT07602088	—	Not yet scored	OngoingRecruiting	60 est.	30 Jan 2029
GUSTO-UKA Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)NCT07242248	—	Locked · track to reveal	OngoingRecruiting	220 est.	5 Mar 2029
Nova-sTARA Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United StatesNCT07309445	—	Not yet scored	OngoingRecruiting	150 est.	31 Mar 2029
cAMeLot-2A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)NCT06852222Bleximenib	Phase 3	Locked · track to reveal	OngoingRecruiting	600 est.	22 Jun 2029
PRIMORDIUMA Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate CancerNCT04557059Radiotherapy	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	692 est.	27 Aug 2029
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative ColitisNCT04372108Ustekinumab	—	Not yet scored	OngoingRecruiting	1,056 est.	31 Aug 2029
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR GeneNCT04794101Genetic: AAV5-hRKp.RPGR Intermediate Dose	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	97 est.	20 Sept 2029
PEGASUSA Study of Guselkumab Treatment Persistence in Psoriatic Arthritis ParticipantsNCT07532226	—	Locked · track to reveal	OngoingRecruiting	200 est.	10 Dec 2029
GERANIUMA Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global RegistryNCT07194070	—	Not yet scored	OngoingRecruiting	175 est.	26 May 2030

View all trials2,499

A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies

Phase 2Active, not recruitingNCT02494986 ↗

Primary completion: Aug 2026; estimated
Enrollment: 48; estimated
Start: Jul 2015; Janssen Sciences Ireland UC

Conditions

Human Immunodeficiency Virus Type 1

Interventions

Rilpivirine

Brief summary

The purpose of this study is to provide continued access to rilpivirine (RPV) for participants who were treated with RPV in a clinical development pediatric study with rilpivirine and who, at the time of roll-over, experience and are expected to continue experiencing clinical benefit from RPV treatment.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2026

Completion date move · 2

Status change · 1

Enrollment change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

LIBERTAS: A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

Phase 3Active, not recruitingNCT05884398 ↗

Primary completion: Oct 2026; estimated
Enrollment: 420; estimated
Start: Aug 2023; Janssen Research & Development, LLC

Conditions

Metastatic Castrate-sensitive Prostate Cancer

Interventions

Apalutamide
Androgen-deprivation Therapy (ADT)

Brief summary

The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level \< 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Dec 2025

Completion date move · 3

Enrollment change · 2

Status change · 2

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Phase 1Active, not recruitingNCT05453903 ↗

Primary completion: Oct 2026; estimated
Enrollment: 196; estimated
Start: Oct 2022; Janssen Research & Development, LLC

Conditions

Leukemia, Myeloid, Acute

Interventions

Bleximenib
Venetoclax (VEN)
Azacitidine (AZA)
Cytarabine
Daunorubicin or Idarubicin

Brief summary

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML directed therapies at the RP2D(s) (dose expansion).

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Mar 2026

Completion date move · 4

Enrollment change · 2

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

PROTEUS: A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Phase 3Active, not recruitingNCT03767244 ↗

Primary completion: Dec 2026; estimated
Enrollment: 2,517; estimated
Start: Jun 2019; Janssen Research & Development, LLC

Conditions

Prostatic Neoplasms

Interventions

Apalutamide
Androgen Deprivation Therapy (ADT)
Placebo

Brief summary

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2026

Completion date move · 2

Status change · 1

Enrollment change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

Phase 3RecruitingNCT06559306 ↗

Primary completion: Dec 2026; estimated
Enrollment: 752; estimated
Start: Jul 2024; Janssen Research & Development, LLC

Conditions

Depressive Disorder, Major

Interventions

Seltorexant
Placebo
Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

Brief summary

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

SunRISe-2: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

Phase 3Active, not recruitingNCT04658862 ↗

Primary completion: Dec 2026; estimated
Enrollment: 518; estimated
Start: Dec 2020; Janssen Research & Development, LLC

Conditions

Urinary Bladder Neoplasms

Interventions

Cetrelimab
TAR-200
Cisplatin
Gemcitabine
Conventional radiation therapy
Hypo-fractioned radiation therapy

Brief summary

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jan 2025

Status change · 1

Enrollment change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

CAN3001: A Long-term Extension Study of PCI-32765 (Ibrutinib)

Phase 3RecruitingNCT01804686 ↗

Primary completion: Dec 2026; estimated
Enrollment: 700; estimated
Start: Sept 2013; Janssen Research & Development, LLC

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Mantle Cell Lymphoma
Follicular Lymphoma
Diffuse Large B-cell Lymphoma
Waldenstrom Macroglobulinemia
Chronic Graft Versus Host Disease

Interventions

Ibrutinib

Brief summary

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jan 2025

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

PLATYPUS: A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

Phase 3RecruitingNCT05179876 ↗

Primary completion: Jan 2027; estimated
Enrollment: 280; estimated
Start: May 2022; Actelion

Conditions

Hypertension, Pulmonary

Interventions

Macitentan
Selexipag
Macitentan/Tadalafil FDC

Brief summary

The purpose of the study is to enable participants with pulmonary hypertension (PH) currently treated with study intervention(s) in a clinical study (parent studies \[NCT03422328, NCT03904693,NCT04565990, NCT02932410, NCT03492177, and NCT04175600\]), to continue to benefit from the intervention after closure of the…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2025

Enrollment change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

PolyDamas: A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

Phase 1Active, not recruitingNCT05908734 ↗

Primary completion: Jan 2027; estimated
Enrollment: 71; estimated
Start: May 2023; Janssen Research & Development, LLC

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Cetrelimab
Amivantamab

Brief summary

The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Apr 2026

Completion date move · 2

Enrollment change · 2

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

QUASAR Jr: A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Phase 3Active, not recruitingNCT06260163 ↗

Primary completion: Feb 2027; estimated
Enrollment: 112; estimated
Start: Jan 2024; Janssen Research & Development, LLC

Conditions

Colitis, Ulcerative

Interventions

Guselkumab Subcutaneous
Guselkumab Intravenous

Brief summary

The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Mar 2026

Status change · 1

Enrollment change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB

Phase 2RecruitingNCT02354014 ↗

Primary completion: Feb 2027; estimated
Enrollment: 60; estimated
Start: May 2016; Janssen Research & Development, LLC

Conditions

Tuberculosis, Multidrug-Resistant

Interventions

Bedaquiline (TMC207)
Background Regimen (BR)

Brief summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and anti-mycobacterial activity of bedaquiline (TMC207) in children and adolescents (0 months to less than \[\<\] 18 years of age) diagnosed with confirmed or probable pulmonary multidrug…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2025

Completion date move · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

CARTITUDE-2: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

Phase 2Active, not recruitingNCT04133636 ↗

Primary completion: Feb 2027; estimated
Enrollment: 208; estimated
Start: Nov 2019; Janssen Research & Development, LLC

Conditions

Multiple Myeloma

Interventions

JNJ-68284528
Lenalidomide
Daratumumab
Bortezomib
Dexamethasone

Brief summary

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

Full record on ClinicalTrials.gov ↗

Change timeline

9 recorded · latest 1 Jan 2026

Enrollment change · 3

Status change · 3

Completion date move · 3

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1Active, not recruitingNCT04108195 ↗

Primary completion: Apr 2027; estimated
Enrollment: 290; estimated
Start: Feb 2020; Janssen Research & Development, LLC

Conditions

Multiple Myeloma

Interventions

Daratumumab
Talquetamab
Teclistamab
Pomalidomide

Brief summary

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Nov 2025

Completion date move · 2

Status change · 1

Enrollment change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

OrigAMI-1: A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Phase 1RecruitingNCT05379595 ↗

Primary completion: Apr 2027; estimated
Enrollment: 225; estimated
Start: Jul 2022; Janssen Research & Development, LLC

Conditions

Advanced or Metastatic Colorectal Cancer

Interventions

Amivantamab IV
Fluorouracil
Leucovorin
Oxaliplatin
Irinotecan
Amivantamab

Brief summary

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts) and to characterize the safety of amivantamab when added to standard-of care…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Apr 2024

Completion date move · 2

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Phase 2RecruitingNCT05327114 ↗

Primary completion: May 2027; estimated
Enrollment: 201; estimated
Start: Sept 2022; Janssen Research & Development, LLC

Conditions

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Interventions

Nipocalimab
Placebo

Brief summary

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Apr 2024

Enrollment change · 1

Completion date move · 1

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

TRIlogy-3: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2RecruitingNCT07266441 ↗

Primary completion: Jun 2027; estimated
Enrollment: 157; estimated
Start: Feb 2026; Janssen Research & Development, LLC

Conditions

Multiple Myeloma

Interventions

JNJ-79635322

Brief summary

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Mar 2026

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Phase 1RecruitingNCT06651229 ↗

Primary completion: Aug 2027; estimated
Enrollment: 155; estimated
Start: Mar 2025; Janssen Research & Development, LLC

Conditions

Leukemia, Myeloid, Acute
Myelodysplastic Neoplasms

Interventions

JNJ-90189892
Azacitadine (AZA)
Venetoclax (VEN)

Brief summary

The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose\[s\] \[RP2Ds\]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk type of myelodysplastic…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 May 2026

Enrollment change · 1

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1Active, not recruitingNCT06604715 ↗

Primary completion: Nov 2027; estimated
Enrollment: 17; estimated
Start: Dec 2024; Janssen Research & Development, LLC

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

JNJ-87562761

Brief summary

The purpose of this study is to determine the recommended phase 2 dose(s) (RP2D\[s\]) of JNJ-87562761 in Part 1 (dose escalation), and to determine the safety and tolerability at RP2D in Part 2 (dose expansion) in participants with multiple myeloma (MM) whose disease has come back after treatment (relapsed) or hasn't…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jan 2025

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

TRI Pro: A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Phase 2RecruitingNCT07589634 ↗

Primary completion: Dec 2027; estimated
Enrollment: 230; estimated
Start: Jul 2026; Janssen Research & Development, LLC

Conditions

Multiple Myeloma

Interventions

Ramantamig
Tocilizumab
Placebo

Brief summary

The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

ICONIC-UC: A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Phase 3RecruitingNCT07196748 ↗

Primary completion: Jan 2028; estimated
Enrollment: 882; estimated
Start: Oct 2025; Janssen Research & Development, LLC

Conditions

Colitis, Ulcerative

Interventions

Icotrokinra
Placebo

Brief summary

The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Nov 2025

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Phase 1Enrolling by invitationNCT06788509 ↗

Primary completion: Jan 2028; estimated
Enrollment: 120; estimated
Start: Dec 2024; Janssen Research & Development, LLC

Conditions

Leukemia, Myeloid, Acute
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-Hodgkin
Myelodysplastic Syndromes
Neoplasms
Solid Tumor, Adult
Prostatic Neoplasms, Castration-Resistant

Interventions

JNJ-75348780
JNJ-67856633
JNJ-54179060
JNJ-64264681
JNJ-74856665
JNJ-70218902
JNJ-64619178
JNJ-80948543

Brief summary

The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the blood and bone marrow in which the bone marrow makes a large number of abnormal blood cells)…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 May 2026

Enrollment change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

Phase 1RecruitingNCT06663319 ↗

Primary completion: Feb 2028; estimated
Enrollment: 260; estimated
Start: Oct 2024; Janssen Research & Development, LLC

Conditions

Colorectal Neoplasms
Gastrointestinal Neoplasms

Interventions

JNJ-89402638
Bevacizumab
FOLFOX
FOLFIRI

Brief summary

The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Mar 2026

Enrollment change · 2

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

AmiNA: A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

Phase 2RecruitingNCT07586202 ↗

Primary completion: Mar 2028; estimated
Enrollment: 68; estimated
Start: Jul 2026; Janssen Research & Development, LLC

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Amivantamab
Lazertinib
Carboplatin
Pemetrexed

Brief summary

The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth factor receptor (EGFR) mutated, Stage II-IIIB non-small cell lung cancer (NSCLC).…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

Phase 1RecruitingNCT07308132 ↗

Primary completion: Aug 2028; estimated
Enrollment: 130; estimated
Start: Jan 2026; Janssen Research & Development, LLC

Conditions

Lymphoma, Non-Hodgkin

Interventions

JNJ-95566692
JNJ-87801493

Brief summary

The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) (Part 1: Dose Escalation) and to further characterize the safety and clinical activity of JNJ-95566692 as a…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Feb 2026

Enrollment change · 1

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

GARDENIA-SLE: A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3RecruitingNCT07438496 ↗

Primary completion: Dec 2028; estimated
Enrollment: 600; estimated
Start: Mar 2026; Janssen Research & Development, LLC

Conditions

Lupus Erythematosus, Systemic

Interventions

Nipocalimab
Placebo
Standard of care treatment

Brief summary

The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs).

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2026

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

cAMeLot-2: A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 3RecruitingNCT06852222 ↗

Primary completion: Jun 2029; estimated
Enrollment: 600; estimated
Start: Jun 2025; Janssen Research & Development, LLC

Conditions

Leukemia, Myeloid, Acute

Interventions

Bleximenib
Venetoclax (VEN)
Azacitidine (AZA)
Placebo

Brief summary

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jul 2025

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab

PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Phase 3Active, not recruitingNCT04557059 ↗

Primary completion: Aug 2029; estimated
Enrollment: 692; estimated
Start: Nov 2020; Janssen Pharmaceutica N.V., Belgium

Conditions

Prostatic Neoplasms

Interventions

Radiotherapy
LHRHa
Apalutamide

Brief summary

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Oct 2024

Completion date move · 2

Enrollment change · 1

Status change · 1

Track Johnson & Johnson drugs to see every change the night it lands.

Track guselkumab